Skip to main
LPCN
LPCN logo

Lipocine (LPCN) Stock Forecast & Price Target

Lipocine (LPCN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lipocine Inc. is positioned for potential revenue growth, particularly with the expected regulatory approval and commercialization of its oral testosterone replacement therapy, TLANDO, in Canada, which management anticipates could significantly enhance topline revenue. The development of LPCN 1154, an oral formulation of brexanolone, showcases promising clinical outcomes, including an impressive remission rate of up to 61% by Day 3, suggesting that it may fulfill substantial unmet medical needs in postpartum depression. Furthermore, the exclusive licensing agreement with Verity for TLANDO in the U.S. underscores strategic partnerships that could bolster market presence and contribute positively to the company's financial outlook.

Bears say

Lipocine Inc reported a net loss of $3.2 million in the third quarter of 2025, indicating ongoing financial challenges as the company advances its drug candidates. The upcoming Phase 3 PPD trial, set to report topline data in the second quarter of 2026, presents significant risks, particularly regarding the potential failure of LPCN 1154 in clinical trials and its subsequent ability to secure regulatory approval and commercial success. Additional concerns include the risk of dilution and competitive pressures that could hinder Lipocine's market entry and performance.

Lipocine (LPCN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lipocine (LPCN) Forecast

Analysts have given Lipocine (LPCN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Lipocine (LPCN) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lipocine (LPCN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.